Dear user, You are using an outdated browser that does not support modern web standards and poses a threat to your safety. For correct display of the site is recommended to install the latest version of any modern browser:

Drug having no analogues in Russia is developed in Ufa

A new drug for treatment of musculoskeletal system, which has no analogues in the Russian pharmaceutical market, is developed in Ufa. A patent was granted to R&D Company "Microgen", in Ufa branch of which a unique technology of effective post-treatment of an aqueous solution of active drug substance "Hondrolon-Pro" was created. The drug is intended for treatment of degenerative diseases of the peripheral synovial joints and spine.

As told by the company's specialists, in contrast to other injectable chondroprotective medicines, the Ufa innovation has stable physical and chemical properties, without addition of an antimicrobial preservative, which may be toxic.

In a series of successive biotech operations samples an improved quality, stable therapeutic effect and a high level of safety were obtained.

In 2014, the volume of sales of injective disease-modifying drugs in Russia amounted to about 4.5 billion rubles. Such drugs were mainly represented by manufacturers of Romania and Germany. The industrial output of the drug will begin after the end of clinical trials, the press service of the R&D Company "Microgen" informs.